CASINVENT

Best-in-class Casein Kinase 1 Inhibitors for Treating Resistant Hematological & Solid Tumors in Advanced Cancer Patients

Contact:
Alexander Scheer, CEO
invest@casinvent.com

The Challenge:

Rising Resistance Caused by Targeted Treatments: Need for Novel Mechanism of Intervention

Advanced melanoma
Before treatment

targeted therapy

Theraphy response

15 weeks post treatment

targeted therapy

Resistance

23 weeks post treatment

No effective second-line therapies for AML, PDAC, and melanoma

10.1200/JCO.2010.33.2312

Resistance Caused by Targeted Treatments on the Rise



Across modalities, across diseases (mainly cancer, leukemia, lymphoma, and muscular degeneration)

Precedence Research Pvt. Ltd.

30% of patients with AML do not respond to **venetoclax/azacytidine** treatment, >50% develop resistance while on treatment

10.1038/s41419-024-06810-7

Quick onset of resistance to chemotherapy in 80-90% PDAC patients

10.3390/ijms20184504

50% of melanoma patients treated with BRAF inhibitors **dabrafenib or vemurafenib** develop disease progression in 6-7 months

10.1016/j.ejca.2015.08.022

Increasing medical need for treatment-resistant tumors: Attractive opportunity for the CasInvent technology

Resistance to Targeted Therapy – Exemplified by AML



Current treatment does not effectively eliminate all leukemic cells



Relapse of leukemia after initial remission



No more treatment option for patients

CASINVENT

CasInvent Inhibitor* for novel effective therapy

* Inhibitors of Casein Kinase 1 Alpha, Delta and Epsilon (CK1α/δ/ε)

AML: Acute Myeloid Leukemia

Blockbuster Potential

Targeted Therapy Market Overview

Current Therapy Causing Resistance	Indication	Total Sales in 2032	Min. potential for CK1 inhibitors*	Est. yearly CK1 sales in 2032
venetoclax	AML/CLL	$2 400 million	>30%	$800 million
gemcitabine	PDAC	$1 200 million	>30%	$400 million
enzalutamide	Prostate	$5 500 million	>20%	$1 100 million
BRAF V600E inhibitor	Melanoma	$5 400 million	>20%	$1 100 million

* Very conservative estimation

Total Addressable Market > $ 3 000 million

Source: Pharma Intelligence database GlobalData Plc, UK

CasInvent's USP: The Most Active and Selective Small-molecule CK1α/δ/ε Inhibitors Known to Date

CasInvent candidate **CI2420B** ready for further development to reach Ph1

- **Only small-molecule inhibitors of all three relevant CK1α/δ/ε isoforms**
- **Simultaneous inhibition of all three isoforms is crucial for anticancer activity**
- **Simultaneous inhibition is crucial for fighting resistance of targeted therapies**



profiled in panel of 400 human kinases, radiometric assay at 1 µM (Reaction Biology)

Our Candidate Molecule CI2420B Works in *In Vivo*

Control

60 mg/kg, s.c. CI2420B

40 mg/kg, s.c. CI2420B

20 mg/kg, s.c. CI2420B



day 21
bioluminescence measurement

CI2420B significantly delays disease progression in an *in vivo* model for AML

CasInvent Pipeline & Priorities

priorities	indication	hit discovery	hit to lead	lead optimization	pre-clinical development	investigational new drug application	clinical trials Phase Ia/Ib	exit
1st liquid tumors	AML/CLL (CI2420B)	*in vivo* PoC				2026/27	2027	2029
2nd solid tumors	PDAC	*in vivo* PoC				2026/27		
3rd solid tumors	Prostate, Melanoma (CI2420B)					TBA		
4nd solid tumors	CRC (TBD)					TBA		
5rd CNS	Huntington, ALS, PD etc (CI1998)	to be partnered with CNS companies (first collaboration started)						

CasInvent Investment Consortium

i&i Biotech Fund

i&i Biotech Fund is an early-stage life sciences fund managing €53 million.
Possibility to co-finance early-stage clinical trials.

KHAN Technology Transfer Fund

KHAN-I is an early-stage life sciences venture fund managing €70 million.
Possibility to co-finance early-stage clinical trials.

Holecek Family Foundation

The Foundation supports organizations with knowledge, experience and vision in areas that the Foundation considers important for the development of our society.
Possibility to co-finance clinical trials.

JIC

The Foundation supports organizations with knowledge, experience and vision in areas that the Foundation considers important for the development of our society.
Possibility to co-finance clinical trials.

The current investors are committed to participate in the planned Series A investment

Road Map to Phase 1



Raising > €10 million in total

CasInvent Team

Alexander Scheer
CEO/CSO
Ex-Merck Serono, **Pierre Fabre**, **Erytech**, **Aelin Therapeutics**
Pharma drug development veteran, 25+ years of experience

Vojtěch Helikar
CFO/COO
Ex-CzechInvest, **CzechTrade,** 10+ years hands-on experience in international business.

Kamil Paruch
Head of Chemistry
Ph.D. at **Columbia University** USA; Associate Professor at **Masaryk University**; 20+ years of experience in kinase drug discovery

Tomasz Radaszkiewicz
Head of Biology
Senior Researcher at **Masaryk University**; author of >25 publications

Natalie Novac
Non-executive Director of BD
Investor Director at Delin Ventures,
Ex-Eli Lilly, Merck KGaA

Tomáš Prát
Head of Alliance Management
Ex-GeneProof and **Contipro**; author of 7 publications (e.g. *Science*) and patent

CasInvent Advisory Board

Vítězslav Bryja
Masaryk University
Professor, group leader at **Masaryk University**; co-inventor of the CasInvent technology; author of >120 scientific publications

David Virshup
National University of SingaporeBrno
Director of the Programme in Cancer and Stem Cell Biology (CSCB) and Professor at **Duke-NUS Medical School**

Uwe Knippschild
University of Ulm
Professor, group leader at the **University of Ulm**; CK1 expert in interactions of CK1 and other signalling pathways

Jackson B. Gibbs
JBG Pharma Consulting
Drug hunter specializing on Oncology and Pharmacology R&D; author >120 research articles, book chapters, and review articles

Peter Nussbaumer
Lead Discovery Center
Medicinal chemistry expert; Managing Director of **LDC** and a partner at **KHAN Technology Transfer Fund I**



Jean-Pierre Bizzari
Former Senior VP at Celgene
renowned oncologist with extensive experience in clinical practice in global pharmaceutical industry

Use of Funds 2026 - 2029

Overview



Development



Operations



CasInvent Achievements

>€5.5 million secured since 2020 (equity + national & international grants)

Eurostars grant €4 million (PANC CKI, 2024) – #1 ranking in CZ, CH, FR (score 51/54) (please see slide 32)

TAČR SIGMA grant – 9th public competition winner (2025)

Transfera Technology Days – 1st place in nationwide competition (2024)

International visibility – part of the Czech Presidential delegation at the Pharma & Biotech Forum, Switzerland (2024)

Investment Opportunity

Seeking > €10 million to advance a high-potential oncology asset toward blockbuster status

Opportunity: Flagship biotech in the Czech republic
Market opportunity – few competitors, high unmet medical need
Planned exit by 2029
Strong ROI potential

Exclusive global IP licensed (Masaryk University, Brno, Czech Republic)
Decades of research expertise
Proven team – science & business

Unique triple CK1 inhibitor drug candidate with strong preclinical data
Milestone-based investment with solid fundamentals

CasInvent Pharma Summary

Portfolio of best-in-class CK1 inhibitors with superb potency and selectivity, ready for successful conclusion of pre-clinical development in 2025

Commercially attractive indications in oncology, including tumors resistant to the state-of-the-art treatment, targeted by new mode of action - efficient inhibition of CK1

Exclusively licensed IP coming from internationally competitive know-how and decades of research at Masaryk University in Brno

CASINVENT

Supplementary Data

Contact:
Alexander Scheer, CEO
invest@casinvent.com

CasInvent Value After Phase I: Comparable Recent Exit Deals

Pharmavant 7 Enters into Licensing Agreement with Eisai (2021)

Small molecules targeting splicing factor 3B subunit 1 against MDS, AML and other leukemias
Single asset, Phase I
Deal value: $393 million

Merck Acquires Imago BioSciences (2023)

Small molecules targeting lysine specific demethylase 1 (LSD-1 or KDM1A)
Phase II in AML and other indications (+ 1 asset in preclinical and 1 asset in discovery phase)
Deal value: $1,350 million

Genentech to Acquire Regor's Portfolio of Next-Gen CDK Inhibitors (2024)

Small-molecule CDK inhibitors for oncology (2 programs in Phase I; not AML-specific)
Multi-asset portfolio, early clinical stage
Deal value: $850 million upfront + undisclosed milestones

Kyowa Kirin Enters Global Strategic Collaboration with Kura Oncology (2024)

Small-molecule menin inhibitor (ziftomenib) targeting NPM1-mutant and KMT2A-rearranged AML
Single asset, registration-directed Phase II
Deal value: $330 million upfront + up to $1 200 million milestones

Source: Pharma Inteligence database GlobalData Plc, UK

Competitive Landscape

Company	Indication	Target	Development Phase	Type
CasInvent Pharma	oncology (AML, solid tumors)	**CK1α, δ, ε**	preclinical	inhibitor
Edgewood Oncology (BTX-A51)	oncology (MDS, AML)	unselective CK1α	clinical Phase I	inhibitor
HealZentx	PTCL	PI3Kδ, CK1ε	Phase III	Inhibitor
Bristol-Myers Squibb	hematologic tumors	CK1α	Phase I Terminated	degrader
GluBio Therapeutics	AML, MDS,	CK1α	Phase I	degrader
The Scripps Research Institute	oncology	CK1δ, ε	preclinical	inhibitor
Pin Therapeutics	oncology	CK1α	IND approval	molecular glue
Stemsynergy Therapeutics	oncology	CK1α	preclinical	activator
Ankar Pharma	ALS, AD	NA	preclinical	inhibitor
Neumora Therapeutics	AD	CK1δ	preclinical	inhibitor
Alchemedicine	circadian rhythm disorders	CK1δ, ε	preclinical	inhibitor
NB Health Laboratory	CNS	CK1δ, ε	preclinical	inhibitor
Intra-Cellular Therapies	autism	NA	preclinical	inhibitor

CasInvent is the only company with triple inhibitor of CK1

Strong Global IP Protection

Protected by the 2019 patent WO2019185631, exclusively licensed, freedom to operate (FTO).

Key Markets:



IP transfer from Masaryk University in progress,
Two novel patent applications (lead compound, chemical synthesis) in progress

How Our Molecule Works:
CI2420B Targets Crucial Pathways in Resistant Cells

a. p53 accumulation:



b. pRB activation (p53-independent):



c. and other pro-survival signaling pathways

Simultaneous inhibition of three disease-relevant CK1α/δ/ε isoforms leads to superior potency in resistant cells

CASINVENT

Contact:
invest@casinvent.com